| Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2012: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
Objective of this study is: 1) to elucidate molecular mechanisms underlying immunosuppressive activity of the newly-found 'regulatory antibody', which shows antigen specificity against nuclear histone H1; and 2) to apply this regulatory antibody to treat proinflammatory disorders.
First, we identified T cell surface cross-reactive antigens, which enabled anti-histone H1 antibody to fulfill its T cell regulatory activity. We also found that the anti-histone H1 antibody not only suppressed type I allergy by acting on mast cells, but also prevented the development of sepsis-like lung injury in mice. These results suggest the effectiveness of anti-histone H1 regulatory antibody against various proinflammatory disorders.
|
